What is Gefitinib 250mg Tablet Geffon used for?
In people Gefitinib 250mg Tablet Geffon with certain types of malignancies, gefitinib is used to treat non-small cell lung cancer that has progressed to other regions of the body. Gefitinib belongs to the kinase inhibitor class of drugs.
When should I take Gefitinib 250mg Tablet Geffon?
As advised by your doctor, Gefitinib 250mg Tablet Geffon should be taken once a day, with or without meals, as advised by Place the tablet in a glass of water (4 to 8 ounces/120 to 240 millilitres) if you have problems swallowing it. After 15 minutes of vigorous stirring Immediately consume the entire combination.
Is Gefitinib 250mg Tablet Geffon effective in the treatment of lung cancer?
Non-small cell lung cancer (NSCLC) with activating EGFR mutations has been documented, but no cured case of advanced NSCLC has been documented yet. The first case of EGFR-mutated lung cancer treated with gefitinib is presented here.
What are the gefitinib side effects?
Tenderness or pain in the abdomen or stomach.
Stools made of clay
A diminished desire to eat
Itching or a rash on the skin.
A feeling of nausea and vomiting
Swelling of the feet or lower legs is a common ailment.
eyes or skin that is yellow.
Is it true that gefitinib causes itching?
In patients on EGFR inhibitors, dry skin is very prevalent; vaginal dryness and itching, perineal dryness, and blepharitis have all been described.
Is gefitinib crushable?
Gefitinib pills are not crushable. You can dissolve the pill in half a glass of water if you can’t swallow it or if you’re using an NG tube to administer the medicine. Allow it to sit for a few moments.
Is gefitinib hazardous to the body?
Because many cytotoxic drugs cause apoptosis, gefitinib may be able to enhance the effects of these drugs by lowering survival stimuli.
Why was gefitinib taken off the market?
It was taken off the market due to an inability to demonstrate therapeutic benefit in numerous randomised trials that did not limit eligibility based on mechanism of action; i.e., eligibility was not confined to patients with NSCLC who had a known EGFR “activating” mutation.
Is gefitinib a first-generation medication?
Gefitinib and erlotinib were the first EGFR tyrosine kinase inhibitors to receive FDA approval for the treatment of individuals with non-small cell lung cancer.
- For more details Click Here.